Discussion
Renal collecting duct carcinoma, considered to originate from the medullary collecting ducts of the kidney, is a very rare subtype of renal cell carcinoma, accounting for 0–3% of all renal malignancies [
4]. The initial observation of the Bellini duct epithelial cells as the source of tumor development, was reported by Cromie W et al [
5]. The 2016 WHO Classification of Tumors of the Urinary System, defined diagnostic criteria for this entity [
6]. CDC is most often found in middle-aged and older patients and more often observed in men than in women [
7]. More than half of the patients with collecting duct cancer, are known to have symptoms at the time of diagnosis. The most common symptom is gross hematuria, followed by back pain or palpable abdominal mass [
8]. Moreover, tumors occurring on the left side have an advantage over those on the right side [
4]. Unlike other renal cell carcinomas, CDC is highly aggressive with extensive metastasis to local lymph nodes. Upon diagnosis, up to 70% of patients have present with metastases to the lymph nodes, lungs and bone marrow, as the most common sites [
7]. In this report, we report a collecting duct carcinoma, which originally presented a retroperitoneal mass on imaging. The renal lesions were undetected.
Through literature review, different hypotheses have been proposed to explain this pathogenesis in the absence of identifiable primary renal tumors.
Mansoor M [
9] reported three cases of extra-renal, renal cell carcinoma and proposed that, the origin of renal tumors in the vicinity of the kidney may include three possible explanations:
1.
The first is assumed to be derived from residual renal embryonic structures that are usually lost in adults, such as mesonephros, or possibly from ectopic renal tissue. For this reason, ectopic renal tissue is often seen in the tumor.
2.
A second explanation is that the primary tumor in the kidney may have regressed. Johnson MT [
10] reported a case of metastatic clear cell renal cell carcinoma located in the adrenal gland. There was a recognizable “degenerative region”, in renal imaging examination, before and after tumor resection, which was suspected to be primary “spontaneous regression” of the kidney.
3.
A final explanation is that the primary tumor in the kidney is very small or cystic, without a solid part. Therefore, imaging modalities cannot detect very small primary renal lesions.
This case falls into the third category, because, during follow-up, in a few months, the renal mass progressed rapidly.
Extrarenal manifestations of collecting duct carcinoma, are a challenge for clinicians and pathologists. Given the lack of specific imaging findings, distinguishing CDC from other tumors by imaging alone, is extremely challenging. Yu Z [
11] described and analyzed the imaging features of 13 cases of CDC, and the results showed that the density of CDC in plain CT scans was higher than that of the surrounding normal tissue, fibroblast proliferation was obvious in the interstitial, the enhancement degree was lower than that of the renal parenchyma on the dynamic, enhanced scan, and the low signal on T2WI MRI was different from that of other RCCs. So it is important to be alert for CDC. Positron emission tomography-computed tomography (PET-CT) has certain limitations in the detection and diagnosis of kidney cancer, and for the CDC, it often exhibits high FDG uptake and is effective in the diagnosis of kidney tumor metastasis [
11]. In view of this, PET-CT examination is recommended after radical nephrectomy to further clarify the systemic situation. The correct diagnosis still depends on the pathological examination. Neoplasms in the posterior peritoneum, adjacent to the kidney, including pheochromocytoma, medullary carcinoma, renal cell carcinoma, or poorly differentiated urothelial carcinoma, should be considered. The most common histomorphological structures observed in CDC, are acinus, tubular, tubular papillary and other growth patterns, with obvious fibrous connective tissue promoting response, inflammatory cell infiltration (mainly of lymphocytes and neutrophils in the interstitium), and the tumor is often accompanied by apoptosis and coagulation necrosis. CDC has a broad spectrum of immunophenotypes. Immunohistochemical analyses revealed CK7, CK19 and CK18 expression in our case, and have also been reported in most of the collecting duct carcinomas. Pheochromocytoma was excluded by: negative immunohistochemistry for Syn and CgA, negativity for OCT3/4 and no lack of INI-1. This made the diagnosis of renal medullary carcinoma unlikely. Positivity for CK7, CK19, and CK18, allowed us to exclude the diagnosis of renal cell carcinoma. Furthermore, the positivity reaction for PAX8, excluded the poorly differentiated urothelial cell carcinoma. Therefore, histopathological examination of the tissue remains as the only precise diagnostic tool.
Clinically, initial diagnosis and treatment decisions for kidney cancer, are often made without histopathological information, based primarily on imaging, and surgical treatment [
12]. According to the literature, most CDC cases are high-grade and advanced, but there is currently no consensus on treatment options. Surgery remains the most effective treatment for kidney cancer patients, even those with advanced disease [
13]. Surgical procedures include radical nephrectomy and partial nephrectomy [
14], but given the high invasiveness of CDC, radical nephrectomy is recommended and may be the only curable opportunity for CDC patients [
15,
16]. The literature reports that the average survival of CDC patients after radical nephrectomy is about 6–13 months [
17‐
19].
Most CDCs reported in the literature are less than satisfactory for adjuvant therapy. Orsola [
20] et al. reported two CDC cases where adjuvant chemotherapy (doxorubicin + gemcitabine) was administered after radical nephrectomy; however, the mean postoperative survival was only 5.6 months. In Husillos’s study [
21], three CDC patients received adjuvant systemic therapy, two received immunotherapy (Sunitinib and Tisimus), and three received a conventional cisplatin chemotherapy regimen. The results showed that the response was very poor, and the survival time was 4 to 7 months However, even with the combination of chemotherapy and targeted therapy, there was no significant improvement in survival time [
22]. All these results indicate that adjuvant therapy is not satisfactory for improving the survival rate of patients, the only treatment that seems likely to cure is surgery.
To sum up, collecting duct carcinoma (CDC) is a highly malignant and rare kidney tumor, the biological behavior and the morphological and functional manifestations of which, have unique characteristics. Most patients with CDC have distant metastasis at the time of the initial diagnosis. The prognosis of CDC is generally poor. Moreover, extensive metastasis to the surrounding lymph nodes and refusal of surgical intervention, were considered as mortality predictors.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.